A meta-analysis of gemcitabine biomarkers in patients with pancreaticobiliary cancers

The objective of this study was to summarize all clinical studies evaluating the prognostic role of gemcitabine (GEM) metabolic genes in pancreaticobiliary (PB) cancer patients receiving GEM therapy in the neoadjuvant, adjuvant, or palliative settings. Meta-analyses were performed to calculate the p...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Pancreas 2013-11, Vol.42 (8), p.1303-1310
Hauptverfasser:	Wei, Christina H, Gorgan, Tristan R, Elashoff, David A, Hines, O Joe, Farrell, James J, Donahue, Timothy R
Format:	Artikel
Sprache:	eng
Schlagworte:	Antimetabolites, Antineoplastic - therapeutic use Biliary Tract Neoplasms - drug therapy Biliary Tract Neoplasms - genetics Biomarkers, Tumor - genetics Chemotherapy, Adjuvant Deoxycytidine - analogs & derivatives Deoxycytidine - therapeutic use Deoxycytidine Kinase - genetics Disease-Free Survival Equilibrative Nucleoside Transporter 1 - genetics Gene Expression Regulation, Neoplastic - drug effects Humans Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - genetics Prognosis Ribonucleoside Diphosphate Reductase - genetics Tumor Suppressor Proteins - genetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!